Tazarotene topical

Drug Profile

Tazarotene topical

Alternative Names: AGN 190168 topical; AGN-190299; Avage; Fabior; Suretin; Tazorac; Zorac

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Allergan
  • Developer Stiefel Laboratories
  • Class Antiacnes; Antipsoriatics; Keratolytics; Nicotinic-acids; Retinoids
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Acne; Psoriasis

Highest Development Phases

  • Marketed Acne vulgaris; Photodamage; Psoriasis

Most Recent Events

  • 12 Jun 2015 Launched for Acne vulgaris in Slovakia, Bulgaria, Croatia, France, Greece, Serbia and Taiwan (Topical, gel) before June 2015
  • 12 Jun 2015 Launched for Psoriasis in Slovakia, Bulgaria, Croatia, France, Greece, Serbia and Taiwan (Topical, gel) before June 2015
  • 12 Jun 2015 No recent reports on development identified - Phase-III for Acne vulgaris in Canada (Topical, foam)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top